1 result(s) for CP-868%2C596 (crenolanib)
| PI Name | Protocol # | Title |
|---|---|---|
| Michael Heinrich | IRB00007264 | Phase II Study of crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors with the D842-related mutations or deletions, including the D842V Mutation in the PDGFRA Gene |
You may qualify for additional trials within our Phase 1 Program